Suit targets 13 generic drug makers “Jumping into the escalating legal battle against pharmaceutical manufacturers, Attorney General Thomas F. Reilly planned to file a lawsuit today against 13 generic drug makers, claiming they overcharged the state Medicaid program $50 million for more than 150 medications.”
Judge Allows Antitrust Case Against Seed Producers “A federal judge on Friday let proceed an antitrust case that accused the Monsanto Company and other big agricultural seed giants of conspiring to control the world’s market in genetically modified crops.”
Definitions Impede Stem-Cell Work The medical promise of embryonic stem-cell research has been plagued by ethical controversy. Now, an apparent way to get stem cells without destroying human embryos is hung up by federal policy.
Bioterror Brain Drain “Infectious-disease specialists are following the big bucks to Washington’s new multibillion-dollar program on bioterrorism research�but at what human cost? “
A dose of reality “The FDA yesterday opened two days of hearings on the subject of consumer advertising, for the first time publicly presenting survey data that shows prescription advertising is generating widespread skepticism among doctors.”
Naturally blonde, brunette… “Designer ‘therapies’ could one day be helping to restore our hair to its former colour and texture”
Venter Announces $500K Prize for Significant Advances Toward $1,000 Genome “Just before lunch today at the GSAC conference, Craig Venter stood before the crowd and announced a mouth-watering proposition: a $500,000 Genomic Technology Prize to be awarded by the J. Craig Venter Science Foundation to a person or organization that develops technology ‘to significantly advance’ […]
The Odd Couple – CombinatoRx brings matchmaking to drug discovery and development While almost everyone in the drug industry is looking for ways to speed new drugs to market, CombinatoRx has taken a particularly pragmatic approach: Rather than looking for new drugs, it is searching for novel combinations of existing drugs with synergistic effects.
GlaxoSmithKline Reveals Ingenuity In a further validation of Big Pharma�s acceptance of systems biology, GlaxoSmithKline has licensed part of the Ingenuity Pathways Knowledge Base to facilitate genome-wide computational analysis of biological systems underlying disease.
The Best in Drugs and Biotech: “S&P’s Herman Saftlas and Frank DiLorenzo share some favorites in these resurgent sectors, including Barr Pharmaceuticals and MedImmune “